Amarin shares could move towards $51 after positive vote, says H.C. Wainwright

Following the "unanimously positive" FDA Advisory Committee meeting yesterday, on the proposed expanded label for Vascepa in cardiovascular risk reduction, H.C. Wainwright analyst Andrew Fein believes further penetration into the at-risk CV patient population could play out. The prospect of an expanded label in CV risk reduction could specifically broaden the market to high triglyceride patients, according to Fein. In comparison to the 6M U.S. patients the analyst approximates with severe hypertriglyceridemia, he estimates prevalence of approximately 60M U.S. patients with high triglyceride levels potentially eligible to be treated under an expanded Vascepa label. Momentum of the positive panel vote and anticipated expanded label approval could move the stock towards $51, says Fein, which is his price target. He keeps a Buy rating on Amarin, which halted yesterday morning at $21.49.